![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 50, 35832-35839, December 10, 1999
,From the Department of Metabolic Diseases, Faculty of Medicine, University of Tokyo, Tokyo 113-8655, Japan
| |
ABSTRACT |
|---|
|
|
|---|
To elucidate the physiological role of sterol
regulatory element-binding protein-1 (SREBP-1), the hepatic mRNA
levels of genes encoding various lipogenic enzymes were estimated in
SREBP-1 gene knockout mice after a fasting-refeeding treatment, which
is an established dietary manipulation for the induction of lipogenic enzymes. In the fasted state, the mRNA levels of all lipogenic enzymes were consistently low in both wild-type and
SREBP-1 Cholesterol and fatty acids are the primary lipids synthesized in
liver. However, biosynthetic pathways for cholesterol and fatty acids
are under distinct and separate regulation (for a review, see Ref. 1).
In contrast to cholesterol synthesis, which is tightly regulated by a
feedback system to maintain cellular cholesterol levels, fatty acid
synthesis is driven primarily by the availability of carbohydrates and
the actions of hormones such as insulin. Despite these different
patterns of regulation, recent evidence suggests that both biosynthetic
pathways can be controlled by a common family of transcription factors
designated sterol regulatory element binding proteins
(SREBPs)1 (reviewed in Ref.
2). SREBPs belong to a large class of transcription factors containing
basic helix-loop-helix-leucine zipper. Unlike other members of this
class, SREBPs are synthesized as membrane-bound precursors that require
cleavage by a two-step proteolytic process in order to release their
amino-terminal basic helix-loop-helix-leucine zipper-containing domain
into the nucleus to activate their target genes in a sterol-regulated
manner (2). Another unique feature of SREBPs is that they have a dual
binding specificity to both classic palindromic E-boxes and
nonpalindromic sterol regulatory elements (SREs) (2-4).
The SREBP target genes include enzymes of cholesterol biosynthesis:
HMG-CoA reductase, HMG-CoA synthase, farnesyl diphosphate synthase,
squalene synthase, and SREBP-2 itself, each of which contains a SRE or
SRE-like sequence in its promoter (5-9). The SREBPs also bind to
regulatory sequences in the promoters of the genes involved in the
biosynthesis of fatty acids: acetyl-CoA carboxylase, fatty acid
synthase, and stearoyl-CoA desaturase (3, 10-12) as well as
glycerol-3-phosphate acyltransferase, a gene involved in the production
of triglycerides (13).
To date, three SREBPs have been identified: SREBP-1a and SREBP-1c,
produced from a single gene through the use of alternate promoters, and
SREBP-2 from a separate gene (2). The rat homologue of SREBP-1c, named
ADD1, was cloned independently as a protein that binds to E-boxes and
presumably promotes adipocyte differentiation (14). All actively
growing cultured cells so far studied produce predominantly SREBP-1a
and SREBP-2, whereas most organs including liver from adult animals
predominantly synthesize SREBP-1c and SREBP-2 (15). All three SREBPs
are capable of activating each of the known target genes, although with
differing efficiencies. SRBP-1c is weaker than SREBP-1a and SREBP-2 due
to its shorter transactivation domain (16, 17).
To gain insight into the distinct roles of each SREBP isoform in
vivo, transgenic mice that overexpress truncated, active nuclear
forms of human SREBP-1a, -1c, or -2 in liver were produced and
characterized (16, 18, 19). The different SREBP-overexpressing transgenic animals showed a different pattern of increase in hepatic synthesis and accumulation of cholesterol and/or fatty acids. These
data suggest that the SREBP-1 isoforms are more selective in activating
fatty acid biosynthetic genes, while SREBP-2 is more specific for
controlling cholesterol biosynthesis. The mechanism for the relative
specificity of each transcription factor is not currently known.
Liver, the principal organ of lipogenesis as well as cholesterogenesis,
is responsible for production of triglycerides from excess dietary
carbohydrate. A high carbohydrate diet induces mRNA levels for a
group of genes designated lipogenic enzymes (reviewed in Refs. 20-22).
This transcriptional induction of lipogenic enzymes is most prominently
seen during fasting-refeeding treatment to rodents. When mice are
fasted, lipogenesis declines. Refeeding fasted animals with a high
carbohydrate diet causes marked induction of the mRNA levels of
lipogenic enzymes to levels higher than pretreatment, which is often
referred to as "overshooting." These lipogenic enzymes include not
only genes for fatty acid biosynthesis, such as acetyl-CoA carboxylase
(ACC), fatty acid synthase (FAS), and stearoyl-CoA desaturase (SCD),
but also glycerol-3-phosphate acyltransferase for triglyceride
synthesis; glucose-6-phosphate dehydrogenase and malic enzyme, which
provide the NADPH for reductive biosynthesis; and ATP citrate lyase,
which produces acetyl-CoA in the cytosol and liver-type pyruvate kinase
in the glycolytic pathway. Each of these lipogenic genes is known to be
regulated at a transcriptional level and has been shown to be activated in the livers of SREBP transgenic mice (16, 18, 23). The distinct
regulation of SREBP-1 and -2 has been observed in the physiological
response of mouse liver to nutritional change. The amounts of SREBP-1c
protein and mRNA, but not those of SREBP-2, dramatically increased
after refeeding fasted mice in a similar manner to lipogenic enzyme
mRNAs (24). Furthermore, transgenic mice overexpressing SREBP-1c,
even when fasted, mimicked the refeeding state of ACC, FAS, and SCD
mRNA levels in wild-type animals (24). Taken together, the data
suggest that a high level expression of nuclear SREBP-1c in the refed
state could be responsible for induction of lipogenic enzymes. However,
due to the artificial overexpression of SREBPs in the transgenic mice,
we cannot conclude whether SREBP-1 is a physiological regulator for
transcription of lipogenic enzymes. The disruption of the SREBP-1 gene
caused partial embryonic lethality, with only 10-30% of expected
homozygous mice surviving (25). In the initial analysis of the
surviving SREBP-1 Animals and Dietary Manipulation--
Mice were housed in colony
cages with a 12-h light/12-h dark cycle. Mice homozygous for disrupted
SREBP-1 gene allele B (SREBP-1 Materials--
Regular laboratory diet and high
carbohydrate/fat-free diet (70% sucrose and 20% casein) were
purchased from Oriental Yeast Co., Ltd. (Osaka, Japan). Rabbit
polyclonal antibody against mouse upstream stimulatory factor (USF)-1
and USF-2 were purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA).
Plasma cholesterol, triglycerides, and nonesterified fatty acids were
measured by enzymatic assays using commercial kits (Determiner TC, TG,
and NEFA, respectively, Kyowa Medics, Co., Ltd., Tokyo, Japan). The
content of cholesterol and triglycerides in liver was measured as
described previously (26).
Nuclear Extract Preparation and Immunoblot Analysis--
Liver
nuclear extracts were prepared as described except for the use of
phenylmethylsulfonyl fluoride (1 mM) instead of Pefabloc (27). The samples of 20-µg nuclear protein were subjected to immunoblot analysis with rabbit IgG against mouse SREBP-1 (amino acids
32-250) (18) or against mouse SREBP-2 (amino acids 32-250) (25),
followed by horseradish peroxidase-linked goat IgG against rabbit IgG
and the ECL kit (Amersham Pharmacia Biotech).
Total RNA Preparation and Blot Hybridization with cDNA
Probes--
Total RNA was extracted from mouse livers and parametrial
adipose tissues using TRIZOL Reagent (Life Technologies, Inc.). Equal
aliquots of total RNA from mice in each group were pooled (total 15 µg), subjected to formalin-denatured agarose electrophoresis, and
transferred to nylon membrane (Hybond N, Amersham Pharmacia Biotech).
Blot hybridization was performed with the cDNA probes labeled with
[
The resulting bands were quantified by exposure of the filters to
BAS2000 with BAStation software (Fuji Photo Film Co., Ltd., Tokyo,
Japan), and the results were normalized to the signal generated from
36B4 mRNA.
Transfections and Luciferase Assays--
Human embryonic kidney
293 cells were grown at 37 °C in an atmosphere of 5%
CO2 in Dulbecco's modified Eagle's medium containing 100 units/ml penicillin and 100 µg/ml streptomycin sulfate supplemented with 10% fetal calf serum. Transfection studies were carried out with
cells plated on 12-well plates as described previously (16) except that
SuperFect (Qiagen) was used for transfection according to the
manufacturer's protocol. The indicated amount of each expression plasmid was transfected simultaneously with 0.25 µg of a luciferase reporter plasmid (pFAS-Luc (16)) and 0.5 µg of a control pTK To show that SREBP-1 controls transcriptional regulation of
hepatic lipogenic enzymes, we hypothesized that the absence of SREBP-1
should cause an impaired response of lipogenic enzyme mRNAs in the
liver to refeeding. To test this hypothesis, we performed a fasting and
refeeding treatment on SREBP-1
/
mice. However, the absence of
SREBP-1 severely impaired the marked induction of hepatic mRNAs of
fatty acid synthetic genes, such as acetyl-CoA carboxylase, fatty acid
synthase, and stearoyl-CoA desaturase, that was observed upon refeeding
in the wild-type mice. Furthermore, the refeeding responses of other
lipogenic enzymes, glycerol-3-phosphate acyltransferase, ATP citrate
lyase, malic enzyme, glucose-6-phosphate dehydrogenase, and S14
mRNAs, were completely abolished in
SREBP-1
/
mice. In contrast, mRNA levels
for cholesterol biosynthetic genes were elevated in the refed
SREBP-1
/
livers accompanied by an increase
in nuclear SREBP-2 protein. When fed a high carbohydrate diet for 14 days, the mRNA levels for these lipogenic enzymes were also
strikingly lower in SREBP-1
/
mice than
those in wild-type mice. These data demonstrate that SREBP-1 plays a
crucial role in the induction of lipogenesis but not cholesterol
biosynthesis in liver when excess energy by carbohydrates is consumed.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice, there were no
significant changes in hepatic mRNA levels of ACC, FAS, and SCD,
while genes in the cholesterol biosynthetic pathway were activated
(25). However, the study was performed in the nonfasted state of a
regular diet, which is not a favorable condition for lipogenesis. In
the current study, the SREBP-1 knockout mice were used to re-estimate
the effects of the absence of functional SREBP-1 protein on expression
of the lipogenic enzymes in an inducible situation (fasting-refeeding
treatment or prolonged high carbohydrate diet). After these dietary
manipulations, wild-type mice showed marked elevation in all lipogenic
genes, while those of SREBP-1
/
mice remained
suppressed, suggesting that SREBP-1 is crucial for nutritional
induction of hepatic lipogenic enzymes.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
) were
prepared as described previously (25) and used for the current studies
with age- (30-33 weeks) and sex-matched wild-type animals on the same
genetic background (hybrid between C57Black/6J and 129 Sv/Ev). For the
fasting and refeeding study, groups of four female
SREBP-1
/
and wild-type mice were set up. All
animals had been fed on a regular chow diet until the fasting and
refeeding treatment started. For the refeeding group, animals were
fasted 24 h (from 22:00 to 22:00) and then refed with a high
carbohydrate/fat-free diet for 12 h (22:00-10:00). This fasting
and refeeding cycle was repeated three times at 3-day intervals for the
refeeding group to adapt the animals to the dietary manipulation. The
final fasting and refeeding cycle was performed after a 1-week
interval. The mean percentage increase in the body weights during the
refeeding was 8% for wild-type and SREBP-1
/
mice. For the fasting group, the animals were fasted for 24 h (10:00-10:00). Both groups were sacrificed between 10:00 and
10:30.
-32P]CTP (6000 Ci/mmol) using the Megaprime DNA
Labeling System (Amersham Pharmacia Biotech). The cDNA probes for
mouse S14, ATP citrate lyase, malic enzyme, liver-type pyruvate kinase,
PPAR
, acyl-CoA oxidase, cytochrome P-450 4A2 (CYP4A2), and acidic
ribosomal phosphoprotein PO (36B4) were prepared by cloning reverse
transcriptase-polymerase chain reaction products from mouse liver RNA
into TA cloning vectors (Invitrogen). The primers used for polymerase
chain reaction were as follows: for rat ATP citrate lyase, 5' primer
was ACATCTGTACCACCTCAGCCATCCAGAA and 3' primer was
GCAGTGGCGTCCACCTTGGCCGCCA (28); for rat liver-type pyruvate kinase, 5'
primer was CCCAGGAGCTGGGCACTGCCTTCTTCCAGC and 3' primer was
AGCCCGTCGTCAATGTAGATGCGGCCCCCCAC (29, 30); for mouse malic enzyme, 5'
primer was CCACCAGCGCGGCTACCTGCTGACGCGGGA and 3' primer was
CCTCTGACTCGCCGGTGCCGCAGCCCGATG (31); for mouse PPAR
, 5'
primer was GCCATGGTGGACACGGAAAGCCCACTCTGCCC and 3' primer was
AGATCAGTACATGTCTCTGTAGATCTCTTG (32); for mouse acyl CoA oxidase, 5'
primer was ATGAATCCCGATCTGCGCAAGGAGC and 3' primer was
AAAGGCATGTAACCCGTAGCACTCC (33); for rat CYP4A2, 5' primer was
CTCTGTATTTAGCCCTACAAGATCCCTGGA and 3' primer was
ATGATAGCCTTGGTGTAGGACCTGGAATTT (34); and for mouse 36B4, 5' primer was
ATGATTATCCAAAATGCTTCATTG and 3' primer was AACAGCATATCCCGAATCTCA (35).
Other probes were as described previously (16, 18).
-gal reference plasmid (Promega). The total amount of DNA in each
transfection was adjusted to 3 µg/well with vector DNA. The amount of
luciferase activity in transfectants was normalized to the amount of
-galactosidase activity as measured by a kit (Promega).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
and
wild-type mice. Table I shows the
phenotypic characteristics of both groups in the study. The mean
percentage increase in body weight during the refeeding was the same
(8%) between refed wild-type and SREBP-1
/
mice. The livers from both refed groups were significantly enlarged, which is customarily observed in refed rodents. Cholesterol content in
the liver was significantly higher in
SREBP-1
/
mice than in wild-type mice in both
fasted and refed states, which is consistent with the previous report
on the nonfasted SREBP-1
/
mice (25). The
fasting-refeeding treatment decreased liver triglyceride content in
SREBP-1
/
mice, while no change was detected
in the livers of wild-type mice. In the wild-type animals, plasma
nonesterified fatty acid levels were elevated by fasting and suppressed
by refeeding. In the SREBP-1
/
mice, the
suppression of plasma NEFA by refeeding seemed more pronounced than
that observed in wild-type mice. There was no significant difference
between SREBP-1
/
and wild-type mice in blood
sugar levels in either nutritional state.
Phenotypic characteristics of wild-type and homozygous
(SREBP-1
/
) mice for the disrupted SREBP-1 gene
/
mice on the
same genetic background had been fed on a regular chow diet. One set of
animals were fasted 24 h, and the other set were fasted 24 h
and refed with high carbohydrate/fat-free diet 12 h prior to
sacrifice at 10:00. *, **, and *** denote significance
versus fasted wild type at p < 0.05, p < 0.01, and p < 0.001, respectively; #, ##, and ### denote significance versus
refed wild type at p < 0.05, p < 0.01, and p < 0.001, respectively; and $, $$, and $$$
denote significance versus fasted
SREBP-1
/
at p < 0.05, p < 0.01, and p < 0.001, respectively.
Fig. 1 shows immunoblot analysis of
SREBPs in liver nuclear extracts. In the fasted state, the mature form
of SREBP-1 in the liver nuclear extracts pooled from wild-type mice was
barely detectable, while refeeding dramatically increased the mature
protein level. The aberrant protein of ~40 kDa derived from the
disrupted SREBP-1 gene in the knockout mice (indicated by an
asterisk in Fig. 1) was also markedly enhanced by refeeding.
This aberrant protein consists of the N-terminal part of the native
SREBP-1 and lacks the helix-loop-helix region, leading to a lack of any
transactivity for SRE-containing promoters (25). The amount of the
SREBP-2 protein in the nuclear extracts from
SREBP-1
/
mice was approximately 2-fold
increased compared with that of wild-type mice in both fasted and refed
states.
|
Figs. 2-5 compare mRNA levels for
various genes in the livers of wild-type and
SREBP-1
/
mice that were fasted, or fasted
and refed. Fig. 2 shows the results for SREBP-1 and -2, SREBP cleavage
activating protein (SCAP), and HMG CoA synthase and reductase. In
accordance with the nuclear protein data, SREBP-1 mRNA level in the
fasted wild-type animals was very low and markedly induced by
refeeding. The aberrant SREBP-1 transcript from the disrupted gene was
also elevated in the refed liver. In contrast, there was no significant
change in mRNA levels of SREBP-2 in the fasted and refed wild-type
mice and in fasted SREBP
/
mice. Refed
SREBP-1
/
mice showed only a slight increase
in SREBP-2 mRNA level as compared with other groups. The mRNA
of SCAP did not change markedly except that refed
SREBP-1
/
mice had a slightly decreased
level, the biological significance of which is currently unknown. The
mRNA levels for both hydroxymethylglutaryl-CoA synthase and
reductase, rate-limiting enzymes in the cholesterol synthetic pathway,
were significantly increased only in refed SREBP
/
mice.
|
Fig. 3 shows changes in mRNA levels
in the genes involved in fatty acid biosynthesis. The acetyl-CoA
carboxylase, fatty acid synthase, and stearoyl-CoA desaturase 1 are
lipogenic enzymes that play a central role in the production of major
long chain monounsaturated fatty acids in mammals by conversion of
acetyl-CoA to palmitoleate (C16:1) and oleate (C18:1). The mRNA
levels of these enzymes were suppressed in livers of fasted wild-type
mice and required longer exposure for signal detection (data not shown; see Table II for reference). They were
markedly elevated in the normal livers by refeeding (Fig. 3). The
mRNA levels for acetyl-CoA carboxylase and fatty acid synthase in
the fasted SREBP-1
/
mice were low and
essentially similar to those of fasted normal mice. However, the
SREBP-1
/
mice had a blunted induction of
these enzymes upon refeeding compared with wild-type mice (Fig. 3 and
Table II). The absence of SREBP-1 caused significant decreases in SCD1
mRNA levels in both fasted and refed states. The most dramatic
differences in the hepatic mRNA levels of refed
SREBP-1
/
mice were observed in other
lipogenic enzymes. As depicted in Fig. 4,
the genes for glycerol-3-phosphate acyltransferase, ATP citrate lyase,
glucose-6-phosphate dehydrogenase, and S14 were markedly activated by
refeeding in the wild-type mice (Fig. 4 and Table II). In contrast,
these refeeding responses were severely reduced in
SREBP-1
/
mice. Notably, the mRNA levels
of glucose-6-phosphate dehydrogenase, glycerol-3-phosphate
acyltransferase, and S14 in the refed
SREBP-1
/
mice remained barely detectable,
similar to their fasting level. The mRNA level of ATP citrate lyase
in the refed SREBP-1
/
livers was also
markedly lower than that in refed wild-type mice. The refeeding
response of malic enzyme in wild type mice was relatively small
(6-fold) as compared with other lipogenic enzymes. This induction of
malic enzyme was also attenuated in SREBP-1
/
mice (Fig. 4 and Table
II). These data suggested that SREBP-1 dominates transcriptional
regulation for those lipogenic enzymes in the liver.
|
|
|
To confirm the validity of the fasting-refeeding protocol in our
studies, we measured mRNA levels for genes that were known to be
regulated by fasting and refeeding but in a different fashion from
lipogenic enzymes. Acyl-CoA oxidase and CYP4A2 are involved in
peroxisomal and microsomal oxidation of fatty acids, respectively. Induction of these enzymes has been shown to be mediated through PPAR
and its ligands (36) and has also been reported to be induced
by fasting and suppressed by refeeding (37). As shown in Fig.
5, both the acyl-CoA oxidase and CYP4A2
mRNAs were 4-fold higher in fasted livers than in refed livers from
both wild-type and SREBP-1
/
mice, confirming
the previous report (37). These data indicate that, as expected,
SREBP-1 has no effect on the message levels of fatty acid oxidation
genes during a fasting-refeeding cycle. The mRNAs of PPAR
were
also found to be regulated in a similar manner to its down stream
genes, suggesting that the transcriptional change of PPAR
could
partially contribute to the nutritional regulation of acyl-CoA oxidase
and CYP4A2 genes.
|
In addition to liver, adipose tissue is another organ in which
lipogenic enzymes are thought to respond to fasting-refeeding at the
transcription level. As shown in Fig. 6,
fasting-refeeding changes in mRNA levels of lipogenic enzymes from
adipose tissues of wild-type mice were less dramatic than those
observed in the liver. Notably, stearoyl-CoA desaturase, glucose-6-P
dehydrogenase, and pyruvate kinase had little response to refeeding.
SREBP-1
/
adipose tissues exhibited impaired induction of other
lipogenic enzymes, although the reduction was generally less pronounced than that observed in the livers with exception of malic enzyme in
which the refeeding pattern was similar in both tissues. Quantification of the relative amount of mRNA is summarized in Table II.
|
Lipogenic enzymes in the liver were also induced when animals were put
on a high carbohydrate diet for a prolonged period of a time. The
promoter regions of lipogenic enzymes such as fatty acid synthase,
liver-type pyruvate kinase, and S14 have been extensively analyzed and
shown to contain cis-acting elements, identified as carbohydrate
(glucose or insulin)-response elements (38-40). To determine the long
term effect of a high carbohydrate diet on hepatic mRNA levels of
lipogenic enzymes, two sets of wild-type and SREBP-1
/
mice were fed
a high sucrose diet and a normal chow diet for 2 weeks. The mice in
this series of experiments were sacrificed in a nonfasted state. The
hepatic mRNA levels for lipogenic genes in the four groups of
animals are shown in Fig. 7. All of the
lipogenic genes were robustly induced by a high carbohydrate diet in
livers of wild type mice as compared with those on a normal diet. The
carbohydrate induction of acetyl-CoA carboxylase, fatty acid synthase,
stearoyl-CoA desaturase, ATP citrate lyase, and pyruvate kinase was
partially blunted in SREBP
/
mice. In contrast, it was almost
abolished in glycerol-3-phosphate acyltransferase, glucose-6-phosphate
dehydrogenase, malic enzyme, and S14. Therefore, the amounts of these
lipogenic enzyme mRNAs after a high carbohydrate diet were
profoundly lower in SREBP-1
/
mice compared with controls, while
differences between groups on a normal chow diet were not striking for
any of lipogenic enzymes. This pattern is very similar to that observed
in the refeeding response.
|
The USFs have been shown to play an important role in the transcription
of fatty acid synthase, S14, and liver pyruvate kinase. To examine the
roles of USFs in conjunction with the deletion of the SREBP-1 gene, we
determined the amounts of USF-1 and -2 in wild-type and
SREBP-1
/
mice by immunoblot analysis (Fig.
8). There was no significant difference
in the amount of USF-1 or -2 protein in the liver nuclear extracts from
SREBP-1
/
and wild-type mice in either fasted
or refed state.
|
The SREBP-1
/
mice produce an aberrant
mRNA and the resulting shortened protein from the disrupted SREBP-1
gene, which has been shown to be inactive for SRE-containing promoters
(25). To exclude a minor possibility that this aberrant protein might
have dominant negative effects on transactivity of lipogenic enzymes,
causing reduction in their mRNA levels, we investigated the effect
of overexpression of the aberrant SREBP-1 protein on fatty acid
synthase promoter activity by luciferase reporter assays (Fig.
9). When the expression vector containing
the cDNA encoding aberrant SREBP-1 protein (25) was transfected
into 293 cells, there was no significant change in the luciferase
activity derived from the reporter gene to which the promoter of fatty
acid synthase was fused (pFAS-Luc) (25). Meanwhile, an expression
vector for an authentic dominant negative version of SREBP-1 that lacks
its N-terminal transactivation domain (41) suppressed the activity of
FAS-luc gene in a dose-dependent manner. These data suggest
that the aberrant SREBP-1 protein does not influence the promoter of
the fatty acid synthase gene in either a negative or positive
fashion.
|
| |
DISCUSSION |
|---|
|
|
|---|
The current study clearly demonstrates that SREBP-1 plays a key
role in hepatic transcriptional regulation of lipogenic enzymes. Deletion of the SREBP-1 gene markedly suppressed expression of an
entire class of lipogenic enzymes in the refed state where lipogenesis
should be fully induced. The similar results from SREBP-1
/
mice fed a high carbohydrate diet
for 2 weeks suggest that SREBP-1 is important for long term as well as
short term induction of lipogenic enzymes. In contrast, in a fasted
state in which lipogenesis should be suppressed, the amount of SREBP-1
in wild-type liver was substantially low at both mRNA and protein
levels. Consequently, there was no marked difference in the fasting
mRNA level of each lipogenic enzyme between wild-type and
SREBP-1
/
mice. Thus, SREBP-1 might not be
involved in maintaining the fasting level of minimal transcription for
lipogenic genes. This also partially explains the lack of a clear
reduction in hepatic mRNA levels of fatty acid synthetic genes in
SREBP-1
/
mice in the initial study where the
animals were sacrificed in a partially fasted state due to their normal
feeding pattern.
The intensity of impairment in refeeding response due to the deletion
of SREBP-1 varies among lipogenic genes in the liver. The most dramatic
suppression in the refed liver was observed in glucose-6-phosphate
dehydrogenase, glycerol-3-phosphate acyltransferase, and malic enzyme,
for which induction of mRNA levels by the refeeding was completely
abolished. SREBP-1 seems to dominate transcriptional regulation for
those enzymes in the liver. The other hepatic lipogenic enzymes were
also grossly suppressed, but they partially retained a refeeding
response in SREBP-1
/
mice. This residual
refeeding response in SREBP-1
/
mice was more
prominent in the adipose tissue. These results suggest that other
factors, presumably helix-loop-helix proteins, could also be involved
in normal refeeding response.
The USFs have been extensively explored as possible transcriptional factors that could be responsible for the nutritional regulation of lipogenic enzymes such as fatty acid synthase, S14, and L-pyruvate kinase through binding to the carbohydrate or insulin-response elements. Both USF-1 and USF-2 homodimers and the heterodimer of the two, which is presumably the physiological form, have been shown to bind to and activate the promoter of those genes (40, 42-44). However, the role of USFs in nutritional responsiveness of lipogenic enzymes has been controversial (45, 46). It should be noted that USFs are relatively abundant proteins and are able to bind the c-Myc E-box. This binding has been thought to contribute to the difficulties encountered in analyzing DNA binding of Myc/Max/Mad network complexes (47). Recently, gene knockout mice for USF-1 and USF-2 have been generated and reported (48, 49). The mRNA levels for fatty acid synthase in the livers of refed mice deficient for USF-1 or -2 were markedly reduced, suggesting that USFs are required for fatty acid synthase gene expression (50). In our study, we showed that the amounts of USF proteins in the nuclear extracts were not changed during fasting and refeeding, whereas the nuclear active mature form of SREBP-1 was markedly suppressed in fasting and induced upon refeeding. It is likely that USFs are essential factors that are required to maintain transcriptional levels of fatty acid synthase irrespective of nutritional state, while SREBP-1 is nutritionally regulatable and is responsible for induced production of fatty acids when excess energy is available. USFs and SREBPs do not appear to compensate for each other in the knockout studies. In addition, in vitro data including gel shift assay have implicated that both USFs and SREBPs bind to the fatty acid synthase promoter independently, and there is no evidence for synergistic action (51). However, these observations supporting mutual independence of USFs from SREBP-1 cannot explain the fact that deficiency of either USFs or SREBP-1 caused profound suppression (70-80%) of fatty acid synthase mRNA upon refeeding. Further investigation of possible mutual interaction of SREBP-1 and USFs is needed to elucidate the molecular mechanism by which SREBP-1 and USFs are involved in activation of the fatty acid synthase gene.
Hasegawa and Uyeda et al. (52) recently identified a novel factor designated glucose response element-binding protein from rat liver nuclear extracts, which binds to glucose response elements of liver pyruvate kinase and fatty acid synthase genes. Estimation of the physiological significance for glucose response element-binding protein awaits its molecular cloning.
Another interesting observation was the regulation of SREBP-1 mRNA
itself in the fasting-refeeding treatment. SREBP-1 mRNA of
wild-type mice was decreased during the fasting and markedly induced
during refeeding in the same manner as other lipogenic enzymes.
Therefore, SREBP-1 is regulated in a lipogenic fashion at both mRNA
and protein levels and could belong to the same family of lipogenic
enzymes. The data from transgenic mice demonstrated that SREBP-1 could
transactivate the SREBP-1 gene itself, which might explain the
overshooting phenomenon of lipogenesis at refeeding by a positive
feedback system in SREBP-1 transcriptional regulation. However, in the
refed SREBP-1
/
mice, an aberrant transcript
derived from the intact promoter of disrupted SREBP-1 gene was also
induced in the same way as native SREBP-1 in the wild-type mice, while
the downstream lipogenic mRNAs were entirely suppressed in the
absence of functional SREBP-1. These data implicate the following
intriguing possibility. Although SREBP-1 directly regulates and its
absence impairs lipogenic enzyme transcription, there may be an
upstream factor or mechanism which controls transcription of SREBP-1.
The primary response to refeeding at this level was normal as
demonstrated by the induction of the aberrant SREBP-1
mRNA.
It is surprising that a single transcriptional factor, SREBP-1, as observed in the current study, can induce such a wide range of genes. Some of the genes analyzed in the current study such as acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase, and glycerol-3-phosphate acyltransferase, have been proven to be a direct target of SREBPs by promoter analysis (3, 10-13). The direct binding of SREBP-1 has yet to be shown for other lipogenic enzyme genes, such as ATP citrate lyase, glucose-6-phosphate dehydrogenase, malic enzyme, pyruvate kinase, and S14. An extensive promoter analysis of these genes might unveil a previously undefined mechanism for the dual binding specificity of SREBPs to SRE and E-box sequences (3) or lead to the discovery of new versions of SRE- or E-box-related sequences.
Impaired nutritional induction of lipogenesis in
SREBP-1
/
mice provides further evidence that
SREBP-1 is more specific to fatty acid synthesis and that SREBP-2 is
more specific to cholesterol synthesis. This is demonstrated by the
fact that activated SREBP-2 in the refed
SREBP-1
/
mice overshot cholesterogenic genes
but was not sufficient to compensate for the lack of SREBP-1 in the
induction of lipogenic enzymes. As expected from the high degree of
homology between SREBP-1 and -2, both molecules have the ability to
bind to and activate the promoters of all cholesterogenic and lipogenic
enzymes studied to date (17-19, 23). The distinct specificities of
SREBP-1 and -2 for lipogenic and cholesterogenic genes in
vivo might be reflective of nutritional activation of SREBP-1 and
-2 at different levels. SREBP-2 regulates cholesterol synthetic genes
through the cleavage of its precursor form to an active nuclear form in a process of interaction with SCAP and proteases in a
sterol-dependent manner. Although it still requires the
cleavage steps, SREBP-1 seems to regulate lipogenesis through its own
mRNA level. Further studies are needed to clarify the nutritional
regulation of glucose and fatty acid metabolism in lipogenic organs and
to understand how insulin and/or glucose or its metabolites could
signal to the transcriptional regulation of lipogenic genes presumably
through SREBP-1. This information is clinically relevant to
understanding the link between glucose and fatty acid metabolism,
because SREBP-1 seems to be involved in insulin resistance as well as
differentiation of adipocytes (53, 54).
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Drs. Michael S. Brown, Joseph L. Goldstein, and Jay D Horton for continuous support for the project. We thank Nobuyoshi Machiyama and Naomi Shimano for preparation of figures.
| |
FOOTNOTES |
|---|
* This work was supported in part by Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research and Health Sciences Research Grants (Research on Human Genome and Gene Therapy) from the Ministry of Health and Welfare.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: 7-3-1 Hongo,
Bunkyo-ku, Tokyo, 113-8655, Japan. Tel.: 81-3-3815-5411 (ext. 33113); Fax: 81-3-5802-2955; E-mail: shimano-tky@umin.ac.jp.
§ Recipient of a fellowship under the Japan Society for the Promotion of Science Postdoctoral Fellowship Program for Foreign Researchers.
¶ Present address: Division of Endocrinology and Metabolism, Dept. of Internal Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
SREBP, sterol
regulatory element-binding protein;
SRE, sterol regulatory element;
ACC, acetyl-CoA carboxylase;
FAS, fatty acid synthase;
SCD, stearoyl-CoA desaturase;
CYP4A2, cytochrome P-450 4A2;
SCAP, SREBP
cleavage activating protein;
PPAR
, peroxisome proliferator-activated
receptor
.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Hillgartner, F. B.,
Salati, L. M.,
and Goodridge, A. G.
(1995)
Physiol. Rev.
75,
47-76 |
| 2. | Brown, M. S., and Goldstein, J. L. (1997) Cell 89, 331-340[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Kim, J. B., Spotts, G. D., Halvorsen, Y. D., Shih, H. M., Ellenberger, T., Towle, H. C., and Spiegelman, B. M. (1995) Mol. Cell. Biol. 15, 2582-2588[Abstract] |
| 4. | Parraga, A., Bellsolell, L., Ferre-D'Amare, A. R., and Burley, S. K. (1998) Structure 6, 661-672[Medline] [Order article via Infotrieve] |
| 5. | Yokoyama, C., Wang, X., Briggs, M. R., Admon, A., Wu, J., Hua, X., Goldstein, J. L., and Brown, M. S. (1993) Cell 75, 187-197[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Hua, X.,
Yokoyama, C.,
Wu, J.,
Briggs, M. R.,
Brown, M. S.,
Goldstein, J. L.,
and Wang, X.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11603-11607 |
| 7. |
Ericsson, J.,
Jackson, S. M.,
Lee, B. C.,
and Edwards, P. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
945-950 |
| 8. |
Guan, G.,
Jiang, G.,
Koch, R. L.,
and Shechter, I.
(1995)
J. Biol. Chem.
270,
21958-21965 |
| 9. |
Sato, R.,
Inoue, J.,
Kawabe, Y.,
Kodama, T.,
Takano, T.,
and Maeda, M.
(1996)
J. Biol. Chem.
271,
26461-26464 |
| 10. |
Kim, J. B.,
and Spiegelman, B. M.
(1996)
Genes Dev.
10,
1096-1107 |
| 11. |
Lopez, J. M.,
Bennett, M. K.,
Sanchez, H. B.,
Rosenfeld, J. M.,
and Osborne, T. E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1049-1053 |
| 12. |
Tabor, D. E.,
Kim, J. B.,
Spiegelman, B. M.,
and Edwards, P. A.
(1998)
J. Biol. Chem.
273,
22052-22058 |
| 13. |
Ericsson, J.,
Jackson, S. M.,
Kim, J. B.,
Spiegelman, B. M.,
and Edwards, P. A.
(1997)
J. Biol. Chem.
272,
7298-7305 |
| 14. |
Tontonoz, P.,
Kim, J. B.,
Graves, R. A.,
and Spiegelman, B. M.
(1993)
Mol. Cell. Biol.
13,
4753-4759 |
| 15. | Shimomura, I., Shimano, H., Horton, J. D., Goldstein, J. L., and Brown, M. S. (1997) J. Clin. Invest. 99, 838-845[Medline] [Order article via Infotrieve] |
| 16. | Shimano, H., Horton, J. D., Shimomura, I., Hammer, R. E., Brown, M. S., and Goldstein, J. L. (1997) J. Clin. Invest. 99, 846-854[Medline] [Order article via Infotrieve] |
| 17. |
Pai, J.,
Guryev, O.,
Brown, M. S.,
and Goldstein, J. L.
(1998)
J. Biol. Chem.
273,
26138-26148 |
| 18. | Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., and Goldstein, J. L. (1996) J. Clin. Invest. 98, 1575-1584[Medline] [Order article via Infotrieve] |
| 19. | Horton, J. D., Shimomura, I., Brown, M. S., Hammer, R. E., Goldstein, J. L., and Shimano, H. (1998) J. Clin. Invest. 101, 2331-2339[Medline] [Order article via Infotrieve] |
| 20. |
Towle, H. C.
(1995)
J. Biol. Chem.
270,
23235-23238 |
| 21. |
Granner, D.,
and Pilkis, S.
(1990)
J. Biol. Chem.
265,
10173-10176 |
| 22. | Goodridge, A. G. (1987) Annu. Rev. Nutr. 7, 157-185[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Shimomura, I.,
Shimano, H.,
Korn, B. S.,
Bashmakov, Y.,
and Horton, J. D.
(1998)
J. Biol. Chem.
273,
35299-35306 |
| 24. |
Horton, J. D.,
Bashmakov, Y.,
Shimomura, I.,
and Shimano, H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5987-5992 |
| 25. | Shimano, H., Shimomura, I., Hammer, R. E., Herz, J., Goldstein, J. L., Brown, M. S., and Horton, J. D. (1997) J. Clin. Invest. 100, 2115-2124[Medline] [Order article via Infotrieve] |
| 26. |
Yokode, M.,
Hammer, R. E.,
Ishibashi, S.,
Brown, M. S.,
and Goldstein, J. L.
(1990)
Science
250,
1273-1275 |
| 27. |
Sheng, Z.,
Otani, H.,
Brown, M. S.,
and Goldstein, J. L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
935-938 |
| 28. |
Elshourbagy, N. A.,
Near, J. C.,
Kmetz, P. J.,
Sathe, G. M.,
Southan, C.,
Strickler, J. E.,
Gross, M.,
Young, J. F.,
Wells, T. N.,
and Groot, P. H.
(1990)
J. Biol. Chem.
265,
1430-1435 |
| 29. |
Noguchi, T.,
Inoue, H.,
Chen, H. L.,
Matsubara, K.,
and Tanaka, T.
(1983)
J. Biol. Chem.
258,
15220-15223 |
| 30. |
Simon, M. P.,
Besmond, C.,
Cottreau, D.,
Weber, A.,
Chaumet-Riffaud, P.,
Dreyfus, J. C.,
Trepat, J. S.,
Marie, J.,
and Kahn, A.
(1983)
J. Biol. Chem.
258,
14576-14584 |
| 31. |
Sul, H. S.,
Wise, L. S.,
Brown, M. L.,
and Rubin, C. S.
(1984)
J. Biol. Chem.
259,
555-559 |
| 32. |
Amri, E. Z.,
Bonino, F.,
Ailhaud, G.,
Abumrad, N. A.,
and Grimaldi, P. A.
(1995)
J. Biol. Chem.
270,
2367-2371 |
| 33. |
Miyazawa, S.,
Hayashi, H.,
Hijikata, M.,
Ishii, N.,
Furuta, S.,
Kagamiyama, H.,
Osumi, T.,
and Hashimoto, T.
(1987)
J. Biol. Chem.
262,
8131-8137 |
| 34. | Heng, Y. M., Kuo, C. S., Jones, P. S., Savory, R., Schulz, R. M., Tomlinson, S. R., Gray, T. J., and Bell, D. R. (1997) Biochem. J. 325, 741-749 |
| 35. |
Krowczynska, A. M.,
Coutts, M.,
Makrides, S.,
and Brawerman, G.
(1989)
Nucleic Acids Res.
17,
6408 |
| 36. |
Ren, B.,
Thelen, A. P.,
Peters, J. M.,
Gonzalez, F. J.,
and Jump, D. B.
(1997)
J. Biol. Chem.
272,
26827-26832 |
| 37. |
Kroetz, D. L.,
Yook, P.,
Costet, P.,
Bianchi, P.,
and Pineau, T.
(1998)
J. Biol. Chem.
273,
31581-31589 |
| 38. |
Moustaid, N.,
Beyer, R. S.,
and Sul, H. S.
(1994)
J. Biol. Chem.
269,
5629-5634 |
| 39. |
Thompson, K. S.,
and Towle, H. C.
(1991)
J. Biol. Chem.
266,
8679-8682 |
| 40. |
Shih, H.,
and Towle, H. C.
(1994)
J. Biol. Chem.
269,
9380-9387 |
| 41. |
Sato, R.,
Yang, J.,
Wang, X.,
Evans, M. J.,
Ho, Y. K.,
Goldstein, J. L.,
and Brown, M. S.
(1994)
J. Biol. Chem.
269,
17267-17273 |
| 42. |
Wang, D.,
and Sul, H. S.
(1995)
J. Biol. Chem.
270,
28716-28722 |
| 43. |
Liu, Z.,
Thompson, K. S.,
and Towle, H. C.
(1993)
J. Biol. Chem.
268,
12787-12795 |
| 44. |
Shih, H. M.,
Liu, Z.,
and Towle, H. C.
(1995)
J. Biol. Chem.
270,
21991-21997 |
| 45. |
Shih, H. M.,
and Towle, H. C.
(1992)
J. Biol. Chem.
267,
13222-13228 |
| 46. |
Kaytor, E. N.,
Shih, H.,
and Towle, H. C.
(1997)
J. Biol. Chem.
272,
7525-7531 |
| 47. |
Sommer, A.,
Bousset, K.,
Kremmer, E.,
Austen, M.,
and Luscher, B.
(1998)
J. Biol. Chem.
273,
6632-6642 |
| 48. |
Vallet, V. S.,
Henrion, A. A.,
Bucchini, D.,
Casado, M.,
Raymondjean, M.,
Kahn, A.,
and Vaulont, S.
(1997)
J. Biol. Chem.
272,
21944-21949 |
| 49. |
Vallet, V. S.,
Casado, M.,
Henrion, A. A.,
Bucchini, D.,
Raymondjean, M.,
Kahn, A.,
and Vaulont, S.
(1998)
J. Biol. Chem.
273,
20175-20179 |
| 50. |
Casado, M.,
Vallet, V. S.,
Kahn, A.,
and Vaulont, S.
(1999)
J. Biol. Chem.
274,
2009-2013 |
| 51. |
Wang, D.,
and Sul, H. S.
(1997)
J. Biol. Chem.
272,
26367-26374 |
| 52. |
Hasegawa, J.,
Osatomi, K.,
Wu, R. F.,
and Uyeda, K.
(1999)
J. Biol. Chem.
274,
1100-1107 |
| 53. | Kim, J. B., Sarraf, P., Wright, M., Yao, K. M., Mueller, E., Solanes, G., Lowell, B. B., and Spiegelman, B. M. (1998) J. Clin. Invest. 101, 1-9[Medline] [Order article via Infotrieve] |
| 54. |
Shimomura, I.,
Hammer, R. E.,
Richardson, J. A.,
Ikemoto, S.,
Bashmakov, Y.,
Goldstein, J. L.,
and Brown, M. S.
(1998)
Genes Dev.
12,
3182-3194 |
This article has been cited by other articles:
![]() |
A. Roth, R. Looser, M. Kaufmann, S. M. Blattler, F. Rencurel, W. Huang, D. D. Moore, and U. A. Meyer Regulatory Cross-Talk between Drug Metabolism and Lipid Homeostasis: Constitutive Androstane Receptor and Pregnane X Receptor Increase Insig-1 Expression Mol. Pharmacol., April 1, 2008; 73(4): 1282 - 1289. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Rasmussen, K. R. Blobaum, Y.-K. Park, S. J. Ehlers, F. Lu, and J.-Y. Lee Lipid Extract of Nostoc commune var. sphaeroides Kutzing, a Blue-Green Alga, Inhibits the Activation of Sterol Regulatory Element Binding Proteins in HepG2 Cells J. Nutr., March 1, 2008; 138(3): 476 - 481. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Jeong, H.-S. Lee, K.-S. Kim, Y.-K. Kim, D. Yoon, and S. W. Park Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2 J. Lipid Res., February 1, 2008; 49(2): 399 - 409. [Abstract] [Full Text] [PDF] |
||||